1
|
Pereira CS, Ribeiro H, Pérez-Cabezas B, Cardoso MT, Alegrete N, Gaspar A, Leão-Teles E, Macedo MF. The GM2 ganglioside inhibits iNKT cell responses in a CD1d-dependent manner. Mol Genet Metab 2018; 125:161-167. [PMID: 30030044 DOI: 10.1016/j.ymgme.2018.07.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Revised: 07/11/2018] [Accepted: 07/11/2018] [Indexed: 02/02/2023]
Abstract
Invariant natural killer T (iNKT) cells are a subset of T lymphocytes that recognize lipid antigens presented on CD1d molecules at the surface of antigen-presenting cells. GM2 is a glycosphingolipid abundant in cellular membranes and known to bind CD1d molecules, but the functional consequences of this binding are not completely clarified. Herein, we analyzed the effect of GM2 in iNKT cell activation. We found that culturing antigen-presenting cells or total peripheral blood mononuclear cells with GM2 did not induce activation of human iNKT cells, implying that this lipid is not antigenic for human iNKT cells. To investigate if this lipid could inhibit iNKT cell activation, we simultaneously incubated antigen-presenting cells with GM2 and the iNKT cell antigen α-Galactosylceramide (α-GalCer) and used them to stimulate iNKT cells. We found that GM2 reduced human iNKT cell activation in a dose-dependent manner. An explanation for this effect could be a direct competition of GM2 with antigenic lipids for CD1d binding. This was demonstrated by the use of an antibody (L363) that stains mouse CD1d:α-GalCer complexes, as in the presence of GM2 the amount of CD1d:α-GalCer complexes are reduced. We further explored the consequences of chronic GM2 overload on human iNKT cells by analyzing iNKT cells in patients diagnosed with GM2 gangliosidoses. We found that pediatric patients present a higher frequency of circulating CD4+ iNKT cells and concomitant lower frequency of CD4-CD8- iNKTs. A lower percentage of iNKT cells expressing the NK marker CD161 was also observed in these patients. In contrast, in two adult patients studied, no differences on iNKT cell phenotype were observed. Altogether, this study uncovers a new role for GM2 in the modulation of iNKT cell activation, thus strengthening the central role of lipid metabolism in iNKT cell biology.
Collapse
Affiliation(s)
- C S Pereira
- CAGE, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal; Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
| | - H Ribeiro
- CAGE, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal; Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal; Departamento de Química, Universidade de Aveiro, Aveiro, Portugal
| | - B Pérez-Cabezas
- CAGE, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal; Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
| | - M T Cardoso
- Centro de Referência de Doenças Hereditárias do Metabolismo (DHM) do Centro Hospitalar de São João, EPE, Medicina Interna, Porto, Portugal
| | - N Alegrete
- Centro de Referência de Doenças Hereditárias do Metabolismo (DHM) do Centro Hospitalar de São João, EPE, Ortopedia, Porto, Portugal
| | - A Gaspar
- Centro de Referência para as Doenças Hereditárias do Metabolismo (DHM) do Centro Hospitalar Lisboa Norte (CHLN), Lisboa, Portugal
| | - E Leão-Teles
- Centro de Referência de Doenças Hereditárias do Metabolismo (DHM) do Centro Hospitalar de São João, EPE, Pediatria, Porto, Portugal
| | - M F Macedo
- CAGE, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal; Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal; Departamento de Ciências Médicas, Universidade de Aveiro, Aveiro, Portugal.
| |
Collapse
|
2
|
Harmatz P, Hendriksz CJ, Lampe C, McGill JJ, Parini R, Leão-Teles E, Valayannopoulos V, Cole TJ, Matousek R, Graham S, Guffon N, Quartel A. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Mol Genet Metab 2017; 122:107-112. [PMID: 28457718 DOI: 10.1016/j.ymgme.2017.03.008] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Revised: 03/30/2017] [Accepted: 03/31/2017] [Indexed: 11/26/2022]
Abstract
Mucopolysaccharidosis (MPS) VI is an autosomal recessive lysosomal storage disorder arising from deficient activity of N-acetylgalactosamine-4-sulfatase (arylsulfatase B) and subsequent intracellular accumulation of the glycosaminoglycans (GAGs) dermatan sulfate and chondroitin-4-sulfate. Manifestations are multi-systemic and include skeletal abnormalities such as dysostosis multiplex and short stature. Reference height-for-age growth charts for treatment-naïve MPS VI patients have been published for both the slowly and rapidly progressing populations. Categorization of disease progression for these charts was based on urinary GAG (uGAG) level; high (>200μg/mg creatinine) levels identified subjects as rapidly progressing. Height data for 141 patients who began galsulfase treatment by the age of 18years were collected and stratified by baseline uGAG level and age at ERT initiation in 3-year increments. The reference MPS VI growth charts were used to calculate change in Z-score from pre-treatment baseline to last follow-up. Among patients with high baseline uGAG levels, galsulfase ERT was associated with an increase in Z-score for those beginning treatment at 0-3, >3-6, >6-9, >9-12, and >12-15years of age (p<0.05). Increases in Z-score were not detected for patients who began treatment between 15 and 18years of age, nor for patients with low (≤200μg/mg creatinine) baseline uGAG levels, regardless of age at treatment initiation. The largest positive deviation from untreated reference populations was seen in the high uGAG excretion groups who began treatment by 6years of age, suggesting an age- and severity-dependent impact of galsulfase ERT on growth.
Collapse
Affiliation(s)
- P Harmatz
- UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.
| | - C J Hendriksz
- University of Pretoria, The Mark Holland Metabolic Unit, Salford Royal Foundation NHS Trust, Salford, UK
| | - C Lampe
- Department of Pediatric and Adolescent Medicine, Villa Metabolica, University Medical Center of the University of Mainz, Germany
| | - J J McGill
- Department of Metabolic Medicine, Lady Cilento Children's Hospital, South Brisbane, QLD, Australia
| | - R Parini
- UOS Malattie Metaboliche Rare, Clinica Pediatrica Ospedale San Gerardo, Monza, Italy
| | - E Leão-Teles
- Unidade Doenças Metabólicas, Hospital Pediátrico Integrado, Centro Hospitalar de S. João, Porto, Portugal
| | - V Valayannopoulos
- Reference Center for Inherited Metabolic Diseases and IMAGINE Institute, Necker-Enfants Malades Hospital, Paris, France
| | - T J Cole
- Population, Policy and Practice Programme, UCL Institute of Child Health, London, UK
| | - R Matousek
- BioMarin Pharmaceutical Inc., Novato, CA, USA
| | - S Graham
- BioMarin Pharmaceutical Inc., Novato, CA, USA
| | - N Guffon
- Reference Center for Inherited Metabolic Diseases, Hôpital Femme Mère Enfant, Lyon, France
| | - A Quartel
- BioMarin Pharmaceutical Inc., Novato, CA, USA
| |
Collapse
|
3
|
Ventura F, Leandro P, Luz A, Rivera I, Silva M, Ramos R, Rocha H, Lopes A, Fonseca H, Gaspar A, Diogo L, Martins E, Leão-Teles E, Vilarinho L, Tavares de Almeida I. Retrospective study of the medium-chain acyl-CoA dehydrogenase deficiency in Portugal. Clin Genet 2013; 85:555-61. [DOI: 10.1111/cge.12227] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2013] [Revised: 07/02/2013] [Accepted: 07/02/2013] [Indexed: 12/30/2022]
Affiliation(s)
- F.V. Ventura
- Department of Biochemistry and Human Biology, Faculty of Pharmacy; University of Lisbon; Lisbon Portugal
| | - P. Leandro
- Department of Biochemistry and Human Biology, Faculty of Pharmacy; University of Lisbon; Lisbon Portugal
| | - A. Luz
- Department of Biochemistry and Human Biology, Faculty of Pharmacy; University of Lisbon; Lisbon Portugal
| | - I.A. Rivera
- Department of Biochemistry and Human Biology, Faculty of Pharmacy; University of Lisbon; Lisbon Portugal
| | - M.F.B. Silva
- Department of Biochemistry and Human Biology, Faculty of Pharmacy; University of Lisbon; Lisbon Portugal
| | - R. Ramos
- Department of Biochemistry and Human Biology, Faculty of Pharmacy; University of Lisbon; Lisbon Portugal
| | - H. Rocha
- Newborn Screening, Metabolism and Genetics Unit, Genetics Department; National Institute of Health Dr. Ricardo Jorge; Porto Portugal
| | - A. Lopes
- Newborn Screening, Metabolism and Genetics Unit, Genetics Department; National Institute of Health Dr. Ricardo Jorge; Porto Portugal
| | - H. Fonseca
- Newborn Screening, Metabolism and Genetics Unit, Genetics Department; National Institute of Health Dr. Ricardo Jorge; Porto Portugal
| | - A. Gaspar
- Department of Pediatrics, Lisbon North Hospital Center; Santa Maria Hospital; Lisbon Portugal
| | - L. Diogo
- Children's Hospital of Coimbra; Metabolic Disorders Unit; Coimbra Portugal
| | - E. Martins
- Children's Hospital Maria Pia; Metabolic Diseases Unit; Porto Portugal
| | - E. Leão-Teles
- S. João Hospital Center; Metabolic Diseases Pediatric Unit; Porto Portugal
| | - L. Vilarinho
- Newborn Screening, Metabolism and Genetics Unit, Genetics Department; National Institute of Health Dr. Ricardo Jorge; Porto Portugal
| | | |
Collapse
|